HHV8 Positive is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma, of which 8 are open and 0 are closed. Of the trials that contain HHV8 Positive and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [5].

HHV8 Positive is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 8 are open and 0 are closed. Of the trials that contain HHV8 Positive and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [5].

HHV8 Positive is an inclusion criterion in 8 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 8 are open and 0 are closed. Of the trials that contain HHV8 Positive and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

HHV8 Positive is an inclusion criterion in 8 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 8 are open and 0 are closed. Of the trials that contain HHV8 Positive and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [5].

HHV8 Positive is an inclusion criterion in 6 clinical trials for double-hit lymphoma, of which 6 are open and 0 are closed. Of the trials that contain HHV8 Positive and double-hit lymphoma as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 6 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 6 are open and 0 are closed. Of the trials that contain HHV8 Positive and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 6 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 6 are open and 0 are closed. Of the trials that contain HHV8 Positive and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 5 clinical trials for triple-hit lymphoma, of which 5 are open and 0 are closed. Of the trials that contain HHV8 Positive and triple-hit lymphoma as inclusion criteria, 4 are phase 2 (4 open) and 1 is phase 2/phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for ALK-positive large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open) and 2 are phase 3 (2 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for grade 3b follicular lymphoma, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and grade 3b follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for intravascular large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and intravascular large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 4 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 4 are open and 0 are closed. Of the trials that contain HHV8 Positive and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 3 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain HHV8 Positive and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma activated B-cell type, of which 3 are open and 0 are closed. Of the trials that contain HHV8 Positive and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 2/phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 3 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 3 are open and 0 are closed. Of the trials that contain HHV8 Positive and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 2 are phase 3 (2 open) [5].

HHV8 Positive is an inclusion criterion in 3 clinical trials for primary effusion lymphoma, of which 3 are open and 0 are closed. Of the trials that contain HHV8 Positive and primary effusion lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HHV8 Positive and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 2 clinical trials for transformed non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HHV8 Positive and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and leiomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for lymphomatoid granulomatosis, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and marginal zone lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for Merkel cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and Merkel cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for multicentric angiofollicular lymphoid hyperplasia, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and multicentric angiofollicular lymphoid hyperplasia as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

HHV8 Positive is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HHV8 Positive and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].